Literature DB >> 25971760

Bisphosphonates: forever or 5 years and stop?

Michael R Kolber1, Cheryl A Sadowski2, Christina Korownyk3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25971760      PMCID： PMC4430061     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN： 0008-350X            Impact factor:   3.275


× No keyword cloud information.
  12 in total

1.  A before-and-after study of fracture risk reporting and osteoporosis treatment initiation.

Authors:  William D Leslie; Suzanne Morin; Lisa M Lix
Journal:  Ann Intern Med       Date:  2010-11-02       Impact factor: 25.391

2.  Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.

Authors:  Dennis M Black; Ann V Schwartz; Kristine E Ensrud; Jane A Cauley; Silvina Levis; Sara A Quandt; Suzanne Satterfield; Robert B Wallace; Douglas C Bauer; Lisa Palermo; Lois E Wehren; Antonio Lombardi; Arthur C Santora; Steven R Cummings
Journal:  JAMA       Date:  2006-12-27       Impact factor: 56.272

Review 3.  Long-term use of bisphosphonates in osteoporosis.

Authors:  Nelson B Watts; Dima L Diab
Journal:  J Clin Endocrinol Metab       Date:  2010-02-19       Impact factor: 5.958

4.  Ten years' experience with alendronate for osteoporosis in postmenopausal women.

Authors:  Henry G Bone; David Hosking; Jean-Pierre Devogelaer; Joseph R Tucci; Ronald D Emkey; Richard P Tonino; Jose Adolfo Rodriguez-Portales; Robert W Downs; Jayanti Gupta; Arthur C Santora; Uri A Liberman
Journal:  N Engl J Med       Date:  2004-03-18       Impact factor: 91.245

5.  Fracture risk remains reduced one year after discontinuation of risedronate.

Authors:  N B Watts; A Chines; W P Olszynski; C D McKeever; M R McClung; X Zhou; A Grauer
Journal:  Osteoporos Int       Date:  2007-10-16       Impact factor: 4.507

6.  Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis.

Authors:  Catherine MacLean; Sydne Newberry; Margaret Maglione; Maureen McMahon; Veena Ranganath; Marika Suttorp; Walter Mojica; Martha Timmer; Alicia Alexander; Melissa McNamara; Sheetal B Desai; Annie Zhou; Susan Chen; Jason Carter; Carlo Tringale; Di Valentine; Breanne Johnsen; Jennifer Grossman
Journal:  Ann Intern Med       Date:  2007-12-17       Impact factor: 25.391

Review 7.  Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.

Authors:  G A Wells; A Cranney; J Peterson; M Boucher; B Shea; V Robinson; D Coyle; P Tugwell
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23

Review 8.  Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.

Authors:  G A Wells; A Cranney; J Peterson; M Boucher; B Shea; V Robinson; D Coyle; P Tugwell
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23

Review 9.  Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.

Authors:  G Wells; A Cranney; J Peterson; M Boucher; B Shea; V Robinson; D Coyle; P Tugwell
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23

10.  Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data.

Authors:  Katy J L Bell; Andrew Hayen; Petra Macaskill; Les Irwig; Jonathan C Craig; Kristine Ensrud; Douglas C Bauer
Journal:  BMJ       Date:  2009-06-23
View more
  1 in total

1.  Osteoporosis in postmenopausal women.

Authors:  Samantha Moe; Allison Paige; G Michael Allan
Journal:  Can Fam Physician       Date:  2021-05       Impact factor: 3.275
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.